EMA Authorised: Anktiva (nogapendekin alfa inbakicept) — Immunitybio Ireland Limited

View source ↗

Summary

EMA authorised Anktiva (nogapendekin alfa inbakicept) for Non-Muscle Invasive Bladder Neoplasms with conditional approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Neoplasms

Drugs mentioned

• Anktiva (N-803)

Snippet

Status: Authorised. Therapeutic area: Non-Muscle Invasive Bladder Neoplasms. MAH: Immunitybio Ireland Limited. Decision date: 11/06/2026. Conditional approval